New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - diltiazem hydrochloride 360mg (30-35 mesh nonpareil seed);   - modified release capsule - 360 mg - active: diltiazem hydrochloride 360mg (30-35 mesh nonpareil seed)   excipient: acetyl tributyl citrate brilliant blue fcf   diethyl phthalate ethanol gelatin methacrylic acid copolymer povidone purified talc   purified water   simeticone sodium laurilsulfate sugar spheres titanium dioxide   - cardizem cd is indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive medications such as diuretics.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - diltiazem hydrochloride, quantity: 360 mg - capsule, modified release - excipient ingredients: purified talc; sodium lauryl sulfate; methacrylic acid copolymer; povidone; simethicone; diethyl phthalate; tributyl acetylcitrate; maize starch; sucrose; titanium dioxide; brilliant blue fcf; potable water; gelatin; silicon dioxide - diltiazem sandoz cd is indicated for the treatment of hypertension. diltiazem sandoz cd is also indicated for the management of chronic stable angina (effort-associated angina) where there is no evidence of vasospastic or unstable angina. since the safety and efficacy of cd capsules in the management of unstable or vasospastic angina has not been substantiated, use of this formulation for these indications is not recommended.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - diltiazem hydrochloride, quantity: 240 mg - capsule, modified release - excipient ingredients: ethylcellulose; simethicone; purified talc; castor oil; tributyl acetylcitrate; white beeswax; methacrylic acid copolymer; titanium dioxide; gelatin; colloidal anhydrous silica; brilliant blue fcf; stearic acid; fumaric acid; maize starch; sucrose - diltiazem sandoz cd is indicated for the treatment of hypertension. diltiazem sandoz cd is also indicated for the management of chronic stable angina (effort-associated angina) where there is no evidence of vasospastic or unstable angina. since the safety and efficacy of cd capsules in the management of unstable or vasospastic angina has not been substantiated, use of this formulation for these indications is not recommended.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - diltiazem hydrochloride, quantity: 180 mg - capsule, modified release - excipient ingredients: fumaric acid; gelatin; methacrylic acid copolymer; brilliant blue fcf; white beeswax; stearic acid; colloidal anhydrous silica; simethicone; ethylcellulose; titanium dioxide; tributyl acetylcitrate; castor oil; purified talc; maize starch; sucrose - diltiazem sandoz cd is indicated for the treatment of hypertension. diltiazem sandoz cd is also indicated for the management of chronic stable angina (effort-associated angina) where there is no evidence of vasospastic or unstable angina. since the safety and efficacy of cd capsules in the management of unstable or vasospastic angina has not been substantiated, use of this formulation for these indications is not recommended.

United States - English - NLM (National Library of Medicine)

akorn - diltiazem hydrochloride (unii: olh94387te) (diltiazem - unii:ee92bbp03h) - diltiazem hydrochloride injection is indicated for the following: 1. atrial fibrillation or atrial flutter. temporary control of rapid ventricular rate in atrial fibrillation or atrial flutter. it should not be used in patients with atrial fibrillation or atrial flutter associated with an accessory bypass tract such as in wolff-parkinson-white (wpw) syndrome or short pr syndrome. 2. paroxysmal supraventricular tachycardia. rapid conversion of paroxysmal supraventricular tachycardias (psvt) to sinus rhythm. this includes av nodal reentrant tachycardias and reciprocating tachycardias associated with an extranodal accessory pathway such as the wpw syndrome or short pr syndrome. unless otherwise contraindicated, appropriate vagal maneuvers should be attempted prior to administration of diltiazem hydrochloride injection. the use of diltiazem hydrochloride injection for control of ventricular response in patients with atrial fibrillation or atrial flutter or conversion to sinus rhythm in patients with psvt should

United States - English - NLM (National Library of Medicine)

akorn - diltiazem hydrochloride (unii: olh94387te) (diltiazem - unii:ee92bbp03h) - diltiazem hydrochloride injection is indicated for the following: - atrial fibrillation or atrial flutter. temporary control of rapid ventricular rate in atrial fibrillation or atrial flutter. it should not be used in patients with atrial fibrillation or atrial flutter associated with an accessory bypass tract such as in wolff-parkinson-white (wpw) syndrome or short pr syndrome. - paroxysmal supraventricular tachycardia. rapid conversion of paroxysmal supraventricular tachycardias (psvt) to sinus rhythm. this includes av nodal reentrant tachycardias and reciprocating tachycardias associated with an extranodal accessory pathway such as the wpw syndrome or short pr syndrome. unless otherwise contraindicated, appropriate vagal maneuvers should be attempted prior to administration of diltiazem hydrochloride injection. the use of diltiazem hydrochloride injection for control of ventricular response in patients with atrial fibrillation or atrial flutter or conversion to sinus rhythm in patients with psvt shou

United States - English - NLM (National Library of Medicine)

medical purchasing solutions, llc - diltiazem hydrochloride (unii: olh94387te) (diltiazem - unii:ee92bbp03h) - diltiazem hydrochloride injection is indicated for the following: - atrial fibrillation or atrial flutter. temporary control of rapid ventricular rate in atrial fibrillation or atrial flutter. it should not be used in patients with atrial fibrillation or atrial flutter associated with an accessory bypass tract such as in wolff-parkinson-white (wpw) syndrome or short pr syndrome. - paroxysmal supraventricular tachycardia. rapid conversion of paroxysmal supraventricular tachycardias (psvt) to sinus rhythm. this includes av nodal reentrant tachycardias and reciprocating tachycardias associated with an extranodal accessory pathway such as the wpw syndrome or short pr syndrome. unless otherwise contraindicated, appropriate vagal maneuvers should be attempted prior to administration of diltiazem hydrochloride injection. the use of diltiazem hydrochloride injection for control of ventricular response in patients with atrial fibrillation or atrial flutter or conversion to sinus rhythm in patients with psvt shou

United States - English - NLM (National Library of Medicine)

avera mckennan hospital - diltiazem hydrochloride (unii: olh94387te) (diltiazem - unii:ee92bbp03h) - diltiazem hydrochloride 120 mg

United States - English - NLM (National Library of Medicine)

cardinal health - diltiazem hydrochloride (unii: olh94387te) (diltiazem - unii:ee92bbp03h) - diltiazem hydrochloride 90 mg

Canada - English - Health Canada

teva canada limited - diltiazem hydrochloride - solution - 5mg - diltiazem hydrochloride 5mg - miscellaneous calcium-channel blocking agents